PulseVision by Escope Tech: Global Leader in Integrated Coronary Morphological and Functional Analysis Platform Submits IPO Prospectus

Coronary heart disease (CHD), also known as coronary atherosclerotic heart disease, refers to heart disease caused by myocardial ischemia and hypoxia resulting from stenosis or occlusion of the coronary artery lumen due to atherosclerosis. Data indicate that 12.9% of annual deaths are attributed to CHD, ranking it among the leading causes of mortality.FirstIn 2022, the number of patients with coronary heart disease (CHD) in China reached 11.39 million, and the incidence and mortality rates of CHD in China continue to rise. The primary challenge in the diagnosis and treatment of CHD is the lack of functional assessment. Maiying, introduced by Yueying Technology, will significantly address this issue, providing decision-making support for clinicians in further treatment.

Artery Select New Product Review, Issue 5, featuringDr. Zhang Chao, CEO of Yueying Technology; Director Zeng Yong, Director of the Third Ward of the Coronary Heart Disease Center at Beijing Anzhen Hospital, Capital Medical University; and Manager Zhao Haijun, Regional Sales Manager at Yueying TechnologyBringing You an Interpretation of Yuying Technology’s Maiying Product

PulseView is a globally leading integrated platform for coronary morphological analysis and evaluation, consisting of two modules: CT-Angio and CT-FFR.

Compared with similar products, Maiying, developed by Yueying Technology, offers the advantages of speed, accuracy, and automation. It can independently perform coronary artery analysis in just 2–3 minutes, with an accuracy rate exceeding 93.3%. Automated data processing ensures that data remains within the hospital. For outpatient screening, it provides one-stop structural and functional analysis with unified algorithms and rapid computation, eliminating repetitive work for physicians. In emergency settings, it meets the stringent time requirements of Chest Pain Centers by quickly completing functional analysis, thereby providing preoperative decision-making guidance for operators.

To provide a more comprehensive understanding, Yueying Technology’s product Maiying will be introduced via live streaming on Artery Selection’s New Product Review from 19:30 to 20:30 on Tuesday, April 11, 2023.

For this event, we have invited Dr. Zhang Chao, CEO of Yueying Technology, to provide an overview of the company; Director Zeng Yong, Head of Ward 3 at the Coronary Heart Disease Center, Beijing Anzhen Hospital, Capital Medical University, to present the product; and Mr. Zhao Haijun, Regional Sales Manager at Yueying Technology, to explain the investment promotion policies during the live broadcast.Welcome everyone to scan the QR code in the poster below to register for the live broadcast:

Dr. Zhang Chao

CEO of Yeying Technology

Previously ranked in the United StatesFirstHe is responsible for the research and design of simulation algorithms at Hopkins Heart, a large-scale cardiac research program at Johns Hopkins Medicine. He previously served as a Senior R&D Engineer at Convergent Science in the United States, where he independently developed multiple computational fluid dynamics (CFD) software packages and programs. He holds a Ph.D. in Mechanical Engineering from Johns Hopkins University, where he studied under the world-renowned fluid dynamicist Dr. Rajat Mittal, focusing on the development of ultra-efficient hemodynamic solvers. He also holds a Master’s degree in Engineering Mechanics from Tsinghua University.

Director Zeng Yong

Chief Physician, Beijing Anzhen Hospital, Capital Medical University

Director of the Third Ward, Coronary Heart Disease Center, Beijing Anzhen Hospital, Capital Medical University; Chief Physician; Doctoral Supervisor; Fellow of the European Society of Cardiology (ESC); Young Committee Member of the Cardiology Branch, Beijing Medical Association; Committee Member of the Cardiac Critical Care Expert Committee, Cross-Strait Medicine and Health Exchange Association; Committee Member of the 9th Atherosclerosis and Coronary Heart Disease Group, Cardiovascular Disease Branch, Chinese Medical Association; Base for Interventional Diagnosis and Treatment Training in Cardiovascular Diseases (Coronary Intervention), Ministry of HealthFirstPhD Supervisor, Corresponding Editorial Board Member of the Chinese Journal of Cardiology, and Reviewer for the Chinese Journal of Preventive Medicine and the Chinese Journal of Diabetes.

Since 1998, engaged in interventional therapy for coronary heart disease, withFirstThe operator has performed over 10,000 coronary intervention procedures, with extensive clinical experience in managing high-risk and complex coronary lesions, such as left main disease, bifurcation lesions, chronic total occlusions, and multivessel disease.

He has presided over and participated in the National Natural Science Foundation of China and multiple national-level research projects. Among these, the project “Clinical Application Research of Intracoronary Ultrasound Imaging” received the Second Prize for Beijing Science and Technology Progress Award in 2000. The research on diagnostic techniques for complex hypertrophic cardiomyopathy was awarded the Third Prize of the Chinese Medical Association Science and Technology Award in 2014 and the Third Prize of the Beijing Municipal Science and Technology Award in 2014. The project “Application of Biomaterials and Delivery Systems in the Treatment of Atherosclerosis” received the Second Prize for Tianjin Science and Technology Progress Award in 2021. He has published more than 80 articles in core journals such as the Chinese Journal of Cardiology and international journals, including 30 SCI-indexed papers. He has contributed to six books, serving as the editor-in-chief of the book series Systemic Diseases and the Heart.

Zhao Haijun, Manager

Regional Sales Manager, Yueying Technology

With 19 years of experience in the medical device industry, possesses a technical and sales background in the cardiovascular and medical imaging sectors. Previously employed at renowned Chinese medical device companies such as Lepu Medical and Keya Medical, has been dedicated to sales and diversified channel development for consumables, equipment, artificial intelligence, and product services.

Yueying Technology, a high-tech enterprise specializing in medical imaging technology services that integrates R&D innovation, scientific research collaboration, and product services, was established in October 2017. The company is committed to building a global professional platform for cardiovascular and cerebrovascular disease imaging and data analysis. Leveraging a standardized evidence-based medicine framework and cutting-edge trends in computational medicine, and underpinned by core technologies such as artificial intelligence, medical imaging, machine vision, simulation science, and data mining, Yueying Technology facilitates a comprehensive upgrade in clinical applications from morphological imaging indicators to functional imaging indicators.

“Artery Select New Product Launch” is a live-streaming series under the “Artery Select” brand, dedicated to supporting medical enterprises in launching innovative products. The program’s mission is to empower every milestone launch of medical innovation products.

Scan the QR code below to contact the assistant and schedule a live stream.

(If already added, please proactively contact the assistant.)